GILEAD SCIENCES 885823 (Seite 98)
eröffnet am 20.02.06 13:18:36 von
neuester Beitrag 13.02.24 21:17:08 von
neuester Beitrag 13.02.24 21:17:08 von
Beiträge: 3.632
ID: 1.041.671
ID: 1.041.671
Aufrufe heute: 0
Gesamt: 481.669
Gesamt: 481.669
Aktive User: 0
ISIN: US3755581036 · WKN: 885823 · Symbol: GILD
62,62
EUR
-0,38 %
-0,24 EUR
Letzter Kurs 23.04.24 Tradegate
Neuigkeiten
| Gilead Sciences Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
22.04.24 · Shareribs Anzeige |
18.04.24 · Shareribs Anzeige |
16.04.24 · Shareribs Anzeige |
12.04.24 · Shareribs Anzeige |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 384,00 | +20,00 | |
| 0,5800 | +19,34 | |
| 10,090 | +17,87 | |
| 5,9050 | +17,86 | |
| 111,15 | +16,77 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 71,33 | -33,92 | |
| 3,6400 | -38,62 | |
| 0,7000 | -61,85 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.567.036 von Klabautermann1958 am 05.05.20 13:07:09
Du hast noch vergessen: sehr hoher Cash-Bestand. Die Liquidität 2. Grades lässt zu das Gilead in der Krise investieren kann.
Zitat von Klabautermann1958: Wieso ist das Papier zu teuer?
KGV von 13, für einen Biotech Wert ist das supergünstig.
Sicherer Dividendenzahler.
Profitabal.
Erfolgreiche Produkte am Markt.
Weitere in der Pipeline...
...es hängt doch gar nicht viel am Remdesivir, das ist nur ein kleiner Teil des Ganzen.
Du hast noch vergessen: sehr hoher Cash-Bestand. Die Liquidität 2. Grades lässt zu das Gilead in der Krise investieren kann.
wieviel Gröten würde Remdesivir in die Kasse von GILEAD SCIENCES spülen?
Antwort auf Beitrag Nr.: 63.577.902 von Deadsh0t am 06.05.20 10:34:47👍 fuer den Artikel
Antwort auf Beitrag Nr.: 63.575.106 von mr11x am 06.05.20 06:08:56Aber laut Gild Pressemitteilung macht Gild weiter, was sie ja nicht würden wenn sie mMn keine Chance auf Erfolg sehen würden (wie auch immer, ich bin nicht vom Fach und kein Vermögensberater und der Aktienkurs in den letzten Tagen unterstützt das Ganze auch nicht so richtig ...)
Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir
Foster City, Calif., May 5, 2020 – Since January, Gilead has worked with speed, care and diligence to prepare for the possibility that the company’s investigational antiviral remdesivir may be found effective against the virus that causes COVID-19. Recent clinical trial results and the decision by the U.S. Food & Drug Administration to issue an Emergency Use Authorization for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.
Gilead’s overarching goal is to make remdesivir both accessible and affordable to governments and patients around the world, where authorized by regulatory authorities. Given the urgent needs of patients globally, the company is pursuing the following strategy to further accelerate and maximize access to remdesivir:
Gilead is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries.
To further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilize their extensive experience providing medicines to low- and middle-income countries during emergency and humanitarian crises to deliver remdesivir using its well-established distribution networks.
Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so.
Gilead is grateful to all its colleagues at health agencies and organizations around the world for their valuable input and insight, which have helped guide the company’s strategy. The company looks forward to keeping its partners and the public updated as plans move forward.
About Remdesivir
Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials, and the safety and efficacy of remdesivir for the treatment of COVID-19 are not yet established. Remdesivir has not been approved by the U.S. FDA for any use. For information about the authorized use of remdesivir and mandatory requirements of the Emergency Use Authorization in the U.S., please review the Fact Sheet for Healthcare Providers and FDA Letter of Authorization available at www.gilead.com/remdesivir.
Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir
Foster City, Calif., May 5, 2020 – Since January, Gilead has worked with speed, care and diligence to prepare for the possibility that the company’s investigational antiviral remdesivir may be found effective against the virus that causes COVID-19. Recent clinical trial results and the decision by the U.S. Food & Drug Administration to issue an Emergency Use Authorization for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.
Gilead’s overarching goal is to make remdesivir both accessible and affordable to governments and patients around the world, where authorized by regulatory authorities. Given the urgent needs of patients globally, the company is pursuing the following strategy to further accelerate and maximize access to remdesivir:
Gilead is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries.
To further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilize their extensive experience providing medicines to low- and middle-income countries during emergency and humanitarian crises to deliver remdesivir using its well-established distribution networks.
Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so.
Gilead is grateful to all its colleagues at health agencies and organizations around the world for their valuable input and insight, which have helped guide the company’s strategy. The company looks forward to keeping its partners and the public updated as plans move forward.
About Remdesivir
Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials, and the safety and efficacy of remdesivir for the treatment of COVID-19 are not yet established. Remdesivir has not been approved by the U.S. FDA for any use. For information about the authorized use of remdesivir and mandatory requirements of the Emergency Use Authorization in the U.S., please review the Fact Sheet for Healthcare Providers and FDA Letter of Authorization available at www.gilead.com/remdesivir.
Trading Spotlight
Antwort auf Beitrag Nr.: 63.567.036 von Klabautermann1958 am 05.05.20 13:07:09Keine Ahnung wie authentisch dieser Bericht wirklich ist, oder Richtung con artist geht?
Some encouraging RDV observations just posted on Twitter by a highly experienced infectious diseases doc in Boston, Francisco Marty, MD @FranciscoMarty_
I thought would write down some practical #tips based on my #qualitative anecdotal experience after personally treating close to 200 patients with #COVID19. For quantitative results, wait for the papers¬—thread
“this juice works, doc!” When you hear similar expressions 1-2 days after starting #remdesivir multiple times, you start to wonder. Don't recall a similar proportion of patients smile after feeling so sick 1-2 days earlier with #COVID19. x/n? Wait for the papers.
Like #treatment for any severe infectious disease (meningitis, Gram-negative bacteremia, influenza pneumonia, etc), earlier is always better. #COVID19 is no different. #Remdesivir stops #SARS-CoV2 replication, but won’t heal the lung injury.
And the lung injury in #COVID19 is nasty and slow to heal, slower that any pneumonic process I ever recall in 25 years in medicine. Patients feel great, appetite comes back, all pains and fevers are gone, but the lung heals slowly.
So my preference on when to use #remdesivir? Use it early in severe #COVID19 disease, anyone with an abnormal chest X-ray that drops to SpO2 <94%: limit the lung injury, get patients home in 2-4 days, not 2 to 4 weeks.
And I would not play number games in terms of age, comorbidities, immunosuppression. If they are sick enough to be in the hospital with #COVID19, sick enough to treat. We see responses in all patient groups, young & old, cancer & transplant, earlier is better.
Patients who end up in the #ICU on mechanical ventilation with #COVID19 likely benefit too given the #ACTT DSMB disclosed info to investigators, but the lung damage is already advanced and takes time to heal, no different that other #lung infections
And yes, several patients who we treated early in their severe #COVID19 disease were able to go home without completing 5 days of #remdesivir. No one has come back yet with recrudescent disease. You can use those vials for others, more beds.
The risk of #hepatotoxicity with #remdesivir is real, 3% of patients needing discontinuation for Hy’s law criteria quoted in the #NIAID press release. Lots of #COVID19 patients come with high ALT/AST though. If <5xULN, treat them, enzymes go down.
The risk for acute #kidney injury is due to the #cyclodextrine used to solubilize #remdesivir. So follow your experience with IV #voriconazole, other drugs in assessing risk/benefit, and consider dosing below GFR <50.
#Cyclodextrine is dialyzable. Although excluded from the study protocols, I would use #remdesivir without qualms in patients on #hemodialysis or #CVVH with severe #COVID19. The #EUA is silent on renal function, risk/benefit.
If patients in the #ICU on #remdesivir treatment defervesce, but then start having fevers again a few days later, please don’t invoke #cytokine storms. Do the basics: look for #VAP, bacteremias, thromboembolic disease, nosocomial stuff.
Pandemic times—we get to use #remdesivir before all the data is out.
#COVID19 is not the #flu & #remdesivir is not #oseltamivir, I think is much better.
We must continue public health measures, get effective #vaccines. This is a first tool delivered to all today, full data soon.
Some encouraging RDV observations just posted on Twitter by a highly experienced infectious diseases doc in Boston, Francisco Marty, MD @FranciscoMarty_
I thought would write down some practical #tips based on my #qualitative anecdotal experience after personally treating close to 200 patients with #COVID19. For quantitative results, wait for the papers¬—thread
“this juice works, doc!” When you hear similar expressions 1-2 days after starting #remdesivir multiple times, you start to wonder. Don't recall a similar proportion of patients smile after feeling so sick 1-2 days earlier with #COVID19. x/n? Wait for the papers.
Like #treatment for any severe infectious disease (meningitis, Gram-negative bacteremia, influenza pneumonia, etc), earlier is always better. #COVID19 is no different. #Remdesivir stops #SARS-CoV2 replication, but won’t heal the lung injury.
And the lung injury in #COVID19 is nasty and slow to heal, slower that any pneumonic process I ever recall in 25 years in medicine. Patients feel great, appetite comes back, all pains and fevers are gone, but the lung heals slowly.
So my preference on when to use #remdesivir? Use it early in severe #COVID19 disease, anyone with an abnormal chest X-ray that drops to SpO2 <94%: limit the lung injury, get patients home in 2-4 days, not 2 to 4 weeks.
And I would not play number games in terms of age, comorbidities, immunosuppression. If they are sick enough to be in the hospital with #COVID19, sick enough to treat. We see responses in all patient groups, young & old, cancer & transplant, earlier is better.
Patients who end up in the #ICU on mechanical ventilation with #COVID19 likely benefit too given the #ACTT DSMB disclosed info to investigators, but the lung damage is already advanced and takes time to heal, no different that other #lung infections
And yes, several patients who we treated early in their severe #COVID19 disease were able to go home without completing 5 days of #remdesivir. No one has come back yet with recrudescent disease. You can use those vials for others, more beds.
The risk of #hepatotoxicity with #remdesivir is real, 3% of patients needing discontinuation for Hy’s law criteria quoted in the #NIAID press release. Lots of #COVID19 patients come with high ALT/AST though. If <5xULN, treat them, enzymes go down.
The risk for acute #kidney injury is due to the #cyclodextrine used to solubilize #remdesivir. So follow your experience with IV #voriconazole, other drugs in assessing risk/benefit, and consider dosing below GFR <50.
#Cyclodextrine is dialyzable. Although excluded from the study protocols, I would use #remdesivir without qualms in patients on #hemodialysis or #CVVH with severe #COVID19. The #EUA is silent on renal function, risk/benefit.
If patients in the #ICU on #remdesivir treatment defervesce, but then start having fevers again a few days later, please don’t invoke #cytokine storms. Do the basics: look for #VAP, bacteremias, thromboembolic disease, nosocomial stuff.
Pandemic times—we get to use #remdesivir before all the data is out.
#COVID19 is not the #flu & #remdesivir is not #oseltamivir, I think is much better.
We must continue public health measures, get effective #vaccines. This is a first tool delivered to all today, full data soon.
Antwort auf Beitrag Nr.: 63.566.472 von Moneymaker123 am 05.05.20 12:19:17Wieso ist das Papier zu teuer?
KGV von 13, für einen Biotech Wert ist das supergünstig.
Sicherer Dividendenzahler.
Profitabal.
Erfolgreiche Produkte am Markt.
Weitere in der Pipeline...
...es hängt doch gar nicht viel am Remdesivir, das ist nur ein kleiner Teil des Ganzen.
KGV von 13, für einen Biotech Wert ist das supergünstig.
Sicherer Dividendenzahler.
Profitabal.
Erfolgreiche Produkte am Markt.
Weitere in der Pipeline...
...es hängt doch gar nicht viel am Remdesivir, das ist nur ein kleiner Teil des Ganzen.
bei den ganzen Shorts die noch zu decken sind kann man sich ,egal was das Präparat
dann nun kosten wird, zurück lehnen und warten bis die Basher Ihre Arbeit gemacht haben.
Erst danach macht es Sinn hier einzusteigen .
ist eh viel zu teuer das Papier!
dann nun kosten wird, zurück lehnen und warten bis die Basher Ihre Arbeit gemacht haben.
Erst danach macht es Sinn hier einzusteigen .
ist eh viel zu teuer das Papier!
Antwort auf Beitrag Nr.: 63.565.986 von Chaecka am 05.05.20 11:46:52Bloomberg. Com
"If Gilead intends to price remdesivir at more than $1 per day, Gilead must fully disclose its research and development costs and all public contributions associated with remdesivir’s development. Then payers and independent experts can analyze again what constitutes fair pricing in a pandemic,” Peter Maybarduk, director at the consumer advocacy organization, said in a statement."
Auch wenn das eine wenig realistische Untergrenze sein dürfte, kann man sich ausmalen, was passiert, wenn Gilead an den oberen Rand der Preisspanne geht.
Vorausgesetzt, das Mittel hat überhaupt eine lebensverlängernde Wirkung.
"If Gilead intends to price remdesivir at more than $1 per day, Gilead must fully disclose its research and development costs and all public contributions associated with remdesivir’s development. Then payers and independent experts can analyze again what constitutes fair pricing in a pandemic,” Peter Maybarduk, director at the consumer advocacy organization, said in a statement."
Auch wenn das eine wenig realistische Untergrenze sein dürfte, kann man sich ausmalen, was passiert, wenn Gilead an den oberen Rand der Preisspanne geht.
Vorausgesetzt, das Mittel hat überhaupt eine lebensverlängernde Wirkung.
Antwort auf Beitrag Nr.: 63.565.773 von Moneymaker123 am 05.05.20 11:35:00
Bitte lies den Originalartikel (bei Bloomberg) und zitiere dann ordentlich! (Der Artikel im Aktionär ist reine Werbung)
Dort steht, dass die 4500 USD die Obergrenze sind und dass der letztliche Preis wohl zwischen 10 und 4500 liegen wird.
Zitat von Moneymaker123: Beste Aussichten.
eine Behandlung aufgeteilt in 10 Tagesdosen liegt zurzeit bei knapp 4.500$
Analysten schätzen das 22 Milliarden duch Remdesivir in die Kassen gespült werden!:
https://www.deraktionaer.de/artikel/aktien/neue-prognose-cor…
Bitte lies den Originalartikel (bei Bloomberg) und zitiere dann ordentlich! (Der Artikel im Aktionär ist reine Werbung)
Dort steht, dass die 4500 USD die Obergrenze sind und dass der letztliche Preis wohl zwischen 10 und 4500 liegen wird.
Durchsuchen
GILEAD SCIENCES 885823
